

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 3, 2017**

**GLOBUS MEDICAL, INC.**  
(Exact name of registrant as specified in charter)

**DELAWARE**  
(State or other jurisdiction  
of incorporation)

**001-35621**  
(Commission  
File Number)

**04-3744954**  
(IRS Employer  
Identification No.)

**2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403**  
(Address of principal executive offices) (Zip Code)

**(610) 930-1800**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 2.02. Results of Operations and Financial Condition.**

On May 3, 2017, we issued a press release reporting, among other things, our sales and operating results for the three month period ended March 31, 2017. A copy of the press release is furnished as Exhibit 99.1 to this report.

In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibits attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

**Item 9.01. Financial Statements and Exhibits.**

**Exhibit No.    Description**

99.1            Press Release dated May 3, 2017

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GLOBUS MEDICAL, INC.**

(Registrant)

Dated: May 3, 2017

**/s/ DANIEL T. SCAVILLA**

Daniel T. Scavilla  
Senior Vice President,  
Chief Financial Officer

**EXHIBIT LIST**

**Exhibit No.    Description**

99.1            Press Release dated May 3, 2017

## Globus Medical Reports First Quarter 2017 Results

AUDUBON, PA, May 3, 2017: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced its financial results for the first quarter ended March 31, 2017.

- Worldwide sales were \$155.8 million, an increase of 11.9% as reported, or 12.1% in constant currency
- First quarter net income was \$28.7 million, or 18.4% of sales
- Diluted earnings per share (EPS) were \$0.30
- Non-GAAP diluted EPS were \$0.32
- Non-GAAP adjusted EBITDA was 37.1% of sales

David Paul, Chairman and CEO said, “Our worldwide sales for the first quarter were \$155.8 million, an increase of 11.9% over the first quarter of 2016. Our adjusted EBITDA margins remained at an outstanding 37.1% and we also delivered non GAAP EPS of \$0.32.

“We are very pleased with our performance during the first quarter. We launched three new spine products, received our first trauma 510(k) clearance, had a strong competitive rep hiring quarter, further expanded our in-house manufacturing capacity, and continued to run an extremely efficient organization with best in class adjusted EBITDA margins. We remain confident in our long-term growth prospects and our ability to sustain industry-leading profitability by continuing to execute on our strategy of rapid product introduction, expansion of our U.S. and international sales footprints, and diligent expense control.”

First quarter sales in the U.S. increased by 1.6% compared to the first quarter of 2016. International sales increased by 123.4% over the first quarter of 2016 on an as reported basis and 126.5% on a constant currency basis due to the Alphatec acquisition included in the first quarter of 2017. Sales from the Alphatec acquisition contributed \$15.2 million in the quarter.

First quarter GAAP net income was \$28.7 million, an increase of 2.5% over the same period last year. Diluted EPS for the first quarter was \$0.30, as compared to \$0.29 for the first quarter 2016. Non-GAAP diluted EPS for the first quarter was \$0.32, compared to \$0.30 in the first quarter of 2016.

The company generated net cash provided by operating activities of \$53.4 million and non-GAAP free cash flow of \$41.9 million in the first quarter. Cash, cash equivalents and marketable securities ended the quarter at \$389.2 million. The company remains debt free.

### 2017 Annual Guidance

The company reaffirms guidance for full year 2017 sales of \$625 million and non-GAAP fully diluted earnings per share of \$1.27.

### Conference Call Information

Globus Medical will hold a teleconference to discuss its 2017 first quarter results with the investment community at 5:30 p.m. Eastern Time today. Globus invites all interested parties to join the call by dialing:

---

1-855-533-7141 United States Participants

1-720-545-0060 International Participants

There is no pass code for the teleconference.

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at [investors.globusmedical.com](http://investors.globusmedical.com).

The call will be archived until Wednesday, May 9, 2017. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 6940-2658.

#### **About Globus Medical, Inc.**

Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.

#### **Non-GAAP Financial Measures**

To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"), management uses certain non-GAAP financial measures. For example, non-GAAP adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation, provision for litigation, and acquisition related costs, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. Our management also uses non-GAAP adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Acquisition related costs represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses including but not limited to costs to exit or convert contractual obligations, severance, and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition-related professional fees.

In addition, for the period ended March 31, 2017 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted earnings per share, which represents net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, acquisition related costs and the tax effects of such adjustments. The tax impact of these non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of litigation, amortization of intangibles, acquisition related costs, and the tax effects of such adjustments, which we believe are not reflective of underlying business trends. Additionally, for the periods ended March 31, 2017 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall liquidity for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency sales growth is calculated by translating current year sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency sales growth provides insight to the comparative increase or decrease

---

in period sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency sales growth are not calculated in conformity with U.S. GAAP within the meaning of Item 10(e) of Regulation S-K. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency sales growth may differ from that of other companies and therefore may not be comparable. Additionally, we have recast prior periods for non-GAAP net income and non-GAAP diluted earnings per share.

#### **Safe Harbor Statements**

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to successfully integrate the international operations acquired from Alphatec, both in general and on our anticipated timeline, our ability to transition Alphatec’s international customers to Globus products, our ability to realize the expected benefits to our results from the Alphatec acquisition, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at [www.sec.gov](http://www.sec.gov). Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

---

**GLOBUS MEDICAL, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
(unaudited)

	Three Months Ended	
	March 31, 2017	March 31, 2016
<i>(In thousands, except per share amounts)</i>		
<b>Sales</b>	<b>\$ 155,809</b>	\$ 139,264
Cost of goods sold	<b>35,600</b>	31,519
<b>Gross profit</b>	<b>120,209</b>	107,745
Operating expenses:		
Research and development	<b>10,666</b>	10,030
Selling, general and administrative	<b>67,059</b>	53,798
Amortization of intangibles	<b>1,782</b>	392
Acquisition related costs	<b>388</b>	674
<b>Total operating expenses</b>	<b>79,895</b>	64,894
<b>Operating income</b>	<b>40,314</b>	42,851
Other income, net	<b>2,100</b>	760
<b>Income before income taxes</b>	<b>42,414</b>	43,611
Income tax provision	<b>13,700</b>	15,601
<b>Net income</b>	<b>\$ 28,714</b>	\$ 28,010
Earnings per share:		
Basic	<b>\$ 0.30</b>	\$ 0.29
Diluted	<b>\$ 0.30</b>	\$ 0.29
Weighted average shares outstanding:		
Basic	<b>95,996</b>	95,398
Diluted	<b>97,148</b>	96,293

**GLOBUS MEDICAL, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**

<i>(In thousands, except par value)</i>	March 31, 2017	December 31, 2016
(unaudited)		
<b>ASSETS</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 182,435	\$ 132,639
Restricted cash	477	477
Short-term marketable securities	143,663	157,673
Accounts receivable, net of allowances of \$3,627 and \$2,771, respectively	94,232	91,983
Inventories	113,037	112,692
Prepaid expenses and other current assets	7,008	14,502
Income taxes receivable	47	3,800
<b>Total current assets</b>	<b>540,899</b>	<b>513,766</b>
Property and equipment, net of accumulated depreciation of \$173,890 and \$166,711, respectively	124,840	124,229
Long-term marketable securities	63,066	60,444
Note receivable	30,000	30,000
Intangible assets, net	61,343	61,706
Goodwill	106,215	105,926
Other assets	954	928
Deferred income taxes	33,104	30,638
<b>Total assets</b>	<b>\$ 960,421</b>	<b>\$ 927,637</b>
<b>LIABILITIES AND EQUITY</b>		
<b>Current liabilities:</b>		
Accounts payable	\$ 17,013	\$ 17,472
Accrued expenses	37,409	46,401
Income taxes payable	11,708	1,911
Business acquisition liabilities, current	9,239	14,108
<b>Total current liabilities</b>	<b>75,369</b>	<b>79,892</b>
Business acquisition liabilities, net of current portion	6,087	5,972
Deferred income taxes	8,261	7,876
Other liabilities	1,819	1,819
<b>Total liabilities</b>	<b>91,536</b>	<b>95,559</b>
<b>Commitments and contingencies</b>		
<b>Equity:</b>		
Common stock; \$0.001 par value. Authorized 785,000 shares; issued and outstanding 96,077 and 95,930 shares at March 31, 2017 and December 31, 2016, respectively	96	96
Additional paid-in capital	217,257	211,725
Accumulated other comprehensive loss	(6,081)	(8,642)
Retained earnings	657,613	628,899
<b>Total equity</b>	<b>868,885</b>	<b>832,078</b>
<b>Total liabilities and equity</b>	<b>\$ 960,421</b>	<b>\$ 927,637</b>

**GLOBUS MEDICAL, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(unaudited)

<i>(In thousands)</i>	Three Months Ended	
	March 31, 2017	March 31, 2016
<b>Cash flows from operating activities:</b>		
Net income	\$ 28,714	\$ 28,010
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	12,240	6,676
Amortization of premium on marketable securities	1,008	953
Write-down for excess and obsolete inventories	1,671	2,225
Stock-based compensation expense	3,491	2,770
Allowance for doubtful accounts	794	88
Change in fair value of contingent consideration	478	—
Change in deferred income taxes	(2,399)	391
(Increase)/decrease in:		
Restricted cash	—	15,668
Accounts receivable	(2,225)	2,201
Inventories	(2,102)	(2,252)
Prepaid expenses and other assets	8,628	1,209
Increase/(decrease) in:		
Accounts payable	(172)	(1,238)
Accrued expenses and other liabilities	(10,170)	(15,661)
Income taxes payable/receivable	13,493	14,517
<b>Net cash provided by operating activities</b>	<b>53,449</b>	<b>55,557</b>
<b>Cash flows from investing activities:</b>		
Purchases of marketable securities	(51,215)	(104,208)
Maturities of marketable securities	55,280	69,656
Sales of marketable securities	6,505	7,798
Purchases of property and equipment	(11,533)	(9,366)
<b>Net cash used in investing activities</b>	<b>(963)</b>	<b>(36,120)</b>
<b>Cash flows from financing activities:</b>		
Payment of business acquisition liabilities	(5,001)	(300)
Proceeds from exercise of stock options	1,990	1,895
<b>Net cash (used in)/provided by financing activities</b>	<b>(3,011)</b>	<b>1,595</b>
Effect of foreign exchange rate on cash	321	91
<b>Net increase in cash and cash equivalents</b>	<b>49,796</b>	<b>21,123</b>
Cash and cash equivalents, beginning of period	132,639	60,152
<b>Cash and cash equivalents, end of period</b>	<b>\$ 182,435</b>	<b>\$ 81,275</b>
Supplemental disclosures of cash flow information:		
Interest paid	8	1
Income taxes paid	\$ 2,656	\$ 774

## Supplemental Financial Information

### Sales by Geographic Area:

(Unaudited) <i>(In thousands)</i>	Three Months Ended	
	March 31, 2017	March 31, 2016
United States	\$ 129,663	\$ 127,560
International	26,146	11,704
<b>Total sales</b>	<b>\$ 155,809</b>	<b>\$ 139,264</b>

### Sales by Product Category:

(Unaudited) <i>(In thousands)</i>	Three Months Ended	
	March 31, 2017	March 31, 2016
Innovative Fusion	\$ 81,872	\$ 70,046
Disruptive Technology	73,937	69,218
<b>Total sales</b>	<b>\$ 155,809</b>	<b>\$ 139,264</b>

### Liquidity and Capital Resources:

(Unaudited) <i>(In thousands)</i>	March 31, 2017	December 31, 2016
Cash and cash equivalents	\$ 182,435	\$ 132,639
Short-term marketable securities	143,663	157,673
Long-term marketable securities	63,066	60,444
<b>Total cash, cash equivalents and marketable securities</b>	<b>\$ 389,164</b>	<b>\$ 350,756</b>
Available borrowing capacity under revolving credit facility	50,000	50,000
Working capital	\$ 465,530	\$ 433,874

The following tables reconcile GAAP to Non-GAAP financial measures.

### Non-GAAP Adjusted EBITDA Reconciliation Table:

(Unaudited) <i>(In thousands, except percentages)</i>	Three Months Ended	
	March 31, 2017	March 31, 2016
Net income	\$ 28,714	\$ 28,010
Interest income, net	(1,418)	(496)
Provision for income taxes	13,700	15,601
Depreciation and amortization	12,240	6,676
<b>EBITDA</b>	<b>53,236</b>	<b>49,791</b>
Stock-based compensation expense	3,491	2,770
Acquisition related costs	1,086	674
<b>Adjusted EBITDA</b>	<b>\$ 57,813</b>	<b>\$ 53,235</b>
Net income as a percentage of sales	18.4%	20.1%
<b>Adjusted EBITDA as a percentage of sales</b>	<b>37.1%</b>	<b>38.2%</b>



### Non-GAAP Net Income Reconciliation Table:

(Unaudited)	Three Months Ended	
	March 31, 2017	March 31, 2016
<i>(In thousands)</i>		
Net income	\$ 28,714	\$ 28,010
Amortization of intangibles	1,782	392
Acquisition related costs	1,086	674
Tax effect of adjusting items	(926)	(382)
Non-GAAP net income	\$ 30,656	\$ 28,694

### Non-GAAP Diluted Earnings Per Share Reconciliation Table:

(Unaudited)	Three Months Ended	
	March 31, 2017	March 31, 2016
<i>(Per share amounts)</i>		
Diluted earnings per share, as reported	\$ 0.30	\$ 0.29
Amortization of intangibles	0.02	—
Acquisition related costs	0.01	0.01
Tax effect of adjusting items	(0.01)	—
Non-GAAP diluted earnings per share	\$ 0.32	\$ 0.30

### Non-GAAP Free Cash Flow Reconciliation Table:

(Unaudited)	Three Months Ended	
	March 31, 2017	March 31, 2016
<i>(In thousands)</i>		
Net cash provided by operating activities	\$ 53,449	\$ 55,557
Adjustment for impact of restricted cash	—	(15,668)
Purchases of property and equipment	(11,533)	(9,366)
Non-GAAP free cash flow	\$ 41,916	\$ 30,523

### Non-GAAP Sales on a Constant Currency Basis Comparative Table:

(Unaudited)	Three Months Ended		Reported Growth	Currency Impact on Current Period	Constant Currency Growth
	March 31, 2017	March 31, 2016			
<i>(In thousands, except percentages)</i>					
United States	\$ 129,663	\$ 127,560	1.6%	—	1.6%
International	26,146	11,704	123.4%	\$ (364)	126.5%
Total sales	\$ 155,809	\$ 139,264	11.9%	\$ (364)	12.1%

#### Contact:

Daniel Scavilla  
Senior Vice President, Chief Financial Officer  
Phone: (610) 930-1800  
Email: [investors@globusmedical.com](mailto:investors@globusmedical.com)  
[www.globusmedical.com](http://www.globusmedical.com)